Evolus boasts early resubmission of FDA-rejected Botox alternative 10-Aug-2018 By Flora Southey Three months after the US FDA vetoed Evolus’ Botox alternative, the firm has announced its resubmission of DWP-450 for approval.
NEWS IN BRIEF US FDA approves first neurotoxin for chronic sialorrhea 06-Jul-2018 By Ben Hargreaves The US FDA has approved Merz’s Xeomin as the first and only neurotoxin available to treat chronic sialorrhea.